SE9500478D0 - New pharmaceutical formulation and process - Google Patents

New pharmaceutical formulation and process

Info

Publication number
SE9500478D0
SE9500478D0 SE9500478A SE9500478A SE9500478D0 SE 9500478 D0 SE9500478 D0 SE 9500478D0 SE 9500478 A SE9500478 A SE 9500478A SE 9500478 A SE9500478 A SE 9500478A SE 9500478 D0 SE9500478 D0 SE 9500478D0
Authority
SE
Sweden
Prior art keywords
alkaline reacting
core material
enteric coating
dosage form
water soluble
Prior art date
Application number
SE9500478A
Other languages
English (en)
Inventor
Per Johan Gunnar Lundberg
Kurt Ingemar Loevgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20397154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9500478(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9500478A priority Critical patent/SE9500478D0/sv
Publication of SE9500478D0 publication Critical patent/SE9500478D0/sv
Priority to MX9604497A priority patent/MX9604497A/es
Priority to US08/612,951 priority patent/US6013281A/en
Priority to AU46839/96A priority patent/AU695774C/en
Priority to BR9605121A priority patent/BR9605121A/pt
Priority to ZA9601078A priority patent/ZA961078B/xx
Priority to PL96316685A priority patent/PL184433B1/pl
Priority to AT96902579T priority patent/ATE218327T1/de
Priority to PT96902579T priority patent/PT752851E/pt
Priority to EP01125523A priority patent/EP1174136A3/en
Priority to KR1019960705620A priority patent/KR100405586B1/ko
Priority to EE9600148A priority patent/EE03379B1/xx
Priority to CNB961900903A priority patent/CN1182841C/zh
Priority to ES96902579T priority patent/ES2179175T3/es
Priority to RU96120189/14A priority patent/RU2170090C2/ru
Priority to CZ19962918A priority patent/CZ291720B6/cs
Priority to DE69621523T priority patent/DE69621523T2/de
Priority to HU9603112A priority patent/HUP9603112A3/hu
Priority to SK1261-96A priority patent/SK281202B6/sk
Priority to DK96902579T priority patent/DK0752851T3/da
Priority to TR96/00785T priority patent/TR199600785T1/xx
Priority to JP52420996A priority patent/JP3881377B2/ja
Priority to PCT/SE1996/000161 priority patent/WO1996024338A1/en
Priority to NZ301424A priority patent/NZ301424A/en
Priority to CA002186037A priority patent/CA2186037C/en
Priority to SI9630509T priority patent/SI0752851T1/xx
Priority to UA96114336A priority patent/UA44890C2/uk
Priority to EP96902579A priority patent/EP0752851B1/en
Priority to IS4359A priority patent/IS1884B/is
Priority to FI964028A priority patent/FI119141B/sv
Priority to NO19964271A priority patent/NO315925B1/no
Priority to HK98109233A priority patent/HK1008302A1/xx
Priority to US09/413,521 priority patent/US20020012676A1/en
Priority to US10/023,968 priority patent/US20020086029A1/en
Priority to US10/235,392 priority patent/US20030113375A1/en
Priority to US10/693,317 priority patent/US20040234594A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
SE9500478A 1995-02-09 1995-02-09 New pharmaceutical formulation and process SE9500478D0 (sv)

Priority Applications (36)

Application Number Priority Date Filing Date Title
SE9500478A SE9500478D0 (sv) 1995-02-09 1995-02-09 New pharmaceutical formulation and process
UA96114336A UA44890C2 (uk) 1995-02-09 1996-02-09 Спосіб одержання фармацевтичної лікарської форми для перорального введення
EP96902579A EP0752851B1 (en) 1995-02-09 1996-02-09 Process for preparing a pharmaceutical formulation
CZ19962918A CZ291720B6 (cs) 1995-02-09 1996-02-09 Způsob přípravy orálního farmaceutického prostředku
SK1261-96A SK281202B6 (sk) 1995-02-09 1996-02-09 Spôsob prípravy orálneho farmaceutického prípravku
AU46839/96A AU695774C (en) 1995-02-09 1996-02-09 New pharmaceutical formulation and process
BR9605121A BR9605121A (pt) 1995-02-09 1996-02-09 Formulação de dosagem farmecêutica oral processo para a preparação de uma formulação de dosagem farmacêutica oral revestida entericamente processo para inibir a secreção ácida gástrica em mamíferos e no ser human e uso de uma formulação de dosagem farmacêutica oral
ZA9601078A ZA961078B (en) 1995-02-09 1996-02-09 New pharamceutical formulation and process.
PL96316685A PL184433B1 (pl) 1995-02-09 1996-02-09 Sposób wytwarzania preparatu farmaceutycznego
AT96902579T ATE218327T1 (de) 1995-02-09 1996-02-09 Verfahren zur herstellung einer pharmazeutischen formulierung
PT96902579T PT752851E (pt) 1995-02-09 1996-02-09 Processo para a preparacao de uma formulacao farmaceutica
EP01125523A EP1174136A3 (en) 1995-02-09 1996-02-09 Oral pharmaceutical dosage form containing a proton pump inhibitor
KR1019960705620A KR100405586B1 (ko) 1995-02-09 1996-02-09 신규한제약제형및이의제조방법
EE9600148A EE03379B1 (et) 1995-02-09 1996-02-09 Enterokattega peroraalse ravimvormi valmistamise protsess
CNB961900903A CN1182841C (zh) 1995-02-09 1996-02-09 新的药物制剂及其制备方法
ES96902579T ES2179175T3 (es) 1995-02-09 1996-02-09 Proceso para preparar una formulacion farmaceutica.
RU96120189/14A RU2170090C2 (ru) 1995-02-09 1996-02-09 Способ получения фармацевтической лекарственной формы, способ ингибирования секреции кислоты в желудке у млекопитающих и человека
MX9604497A MX9604497A (es) 1995-02-09 1996-02-09 Nueva formulacion farmaceutica y procedimiento.
DE69621523T DE69621523T2 (de) 1995-02-09 1996-02-09 Verfahren zur herstellung einer pharmazeutischen formulierung
HU9603112A HUP9603112A3 (en) 1995-02-09 1996-02-09 New pharmaceutical formulation and process for its production
US08/612,951 US6013281A (en) 1995-02-09 1996-02-09 Method of making a pharmaceutical dosage form comprising a proton pump inhibitor
DK96902579T DK0752851T3 (da) 1995-02-09 1996-02-09 Fremgangsmåde til fremstilling af et farmaceutisk præparat
TR96/00785T TR199600785T1 (tr) 1995-02-09 1996-02-09 Yeni ispenciyari formülasyonlar ve metodu.
JP52420996A JP3881377B2 (ja) 1995-02-09 1996-02-09 新規な製剤および方法
PCT/SE1996/000161 WO1996024338A1 (en) 1995-02-09 1996-02-09 New pharmaceutical formulation and process
NZ301424A NZ301424A (en) 1995-02-09 1996-02-09 Manufacture of coated tablet with two functionally different layers one being a core material containing a proton pump inhibitor
CA002186037A CA2186037C (en) 1995-02-09 1996-02-09 New pharmaceutical formulation and process
SI9630509T SI0752851T1 (en) 1995-02-09 1996-02-09 Process for preparing a pharmaceutical formulation
IS4359A IS1884B (is) 1995-02-09 1996-09-17 Aðferð til að framleiða lyf á skammtaformi til inntöku um munn sem inniheldur prótónupumpuhemil
NO19964271A NO315925B1 (no) 1995-02-09 1996-10-08 Fremgangsmåte for fremstilling av en oral farmasöytisk doseringsform, og anvendelse derav
FI964028A FI119141B (sv) 1995-02-09 1996-10-08 Förfarande för framställning av en farmaceutisk formulering
HK98109233A HK1008302A1 (en) 1995-02-09 1998-07-17 Process for preparing a pharmaceutical formulation
US09/413,521 US20020012676A1 (en) 1995-02-09 1999-10-06 New pharmaceutical formulation and process
US10/023,968 US20020086029A1 (en) 1995-02-09 2001-12-18 Pharmaceutical formulation and process
US10/235,392 US20030113375A1 (en) 1995-02-09 2002-09-04 Pharmaceutical formulation and process
US10/693,317 US20040234594A1 (en) 1995-02-09 2003-10-23 Pharmaceutical formulation and process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9500478A SE9500478D0 (sv) 1995-02-09 1995-02-09 New pharmaceutical formulation and process

Publications (1)

Publication Number Publication Date
SE9500478D0 true SE9500478D0 (sv) 1995-02-09

Family

ID=20397154

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9500478A SE9500478D0 (sv) 1995-02-09 1995-02-09 New pharmaceutical formulation and process

Country Status (29)

Country Link
US (5) US6013281A (sv)
EP (2) EP0752851B1 (sv)
JP (1) JP3881377B2 (sv)
KR (1) KR100405586B1 (sv)
CN (1) CN1182841C (sv)
AT (1) ATE218327T1 (sv)
BR (1) BR9605121A (sv)
CA (1) CA2186037C (sv)
CZ (1) CZ291720B6 (sv)
DE (1) DE69621523T2 (sv)
DK (1) DK0752851T3 (sv)
EE (1) EE03379B1 (sv)
ES (1) ES2179175T3 (sv)
FI (1) FI119141B (sv)
HK (1) HK1008302A1 (sv)
HU (1) HUP9603112A3 (sv)
IS (1) IS1884B (sv)
MX (1) MX9604497A (sv)
NO (1) NO315925B1 (sv)
NZ (1) NZ301424A (sv)
PL (1) PL184433B1 (sv)
PT (1) PT752851E (sv)
RU (1) RU2170090C2 (sv)
SE (1) SE9500478D0 (sv)
SK (1) SK281202B6 (sv)
TR (1) TR199600785T1 (sv)
UA (1) UA44890C2 (sv)
WO (1) WO1996024338A1 (sv)
ZA (1) ZA961078B (sv)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US6248758B1 (en) * 1997-03-13 2001-06-19 Hexal Ag Pharmaceutical antacid
AU7375598A (en) * 1997-05-09 1998-11-27 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
CN1268137A (zh) 1997-07-03 2000-09-27 杜邦药品公司 治疗神经失调的咪唑并嘧啶和咪唑并吡啶
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
PL195266B1 (pl) * 1997-12-08 2007-08-31 Altana Pharma Ag Jednostka związku aktywnego nietrwałego w środowisku kwaśnym, sposób jej otrzymywania, czopki zawierające aktywny związek nietrwały w środowisku kwaśnym oraz sposób ich otrzymywania
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
WO1999053918A1 (fr) 1998-04-20 1999-10-28 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
JP4988088B2 (ja) 1998-08-12 2012-08-01 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジン−２−イルメチルスルフィニル−１ｈ−ベンズイミダゾール、もしくはピリジン−２−イルメチルスルフィニル−１ｈ−ベンズイミダゾールの骨格を有する化合物、またはその薬学的に許容される塩の経口投与形組成物を固定的に組み合わせた組成物
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US7365047B1 (en) * 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
MXPA03011017A (es) * 2001-06-01 2005-04-29 Pozen Inc Composiciones farmaceuticas para la entrega coordinada de nsaids.
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
WO2003000239A1 (en) * 2001-06-21 2003-01-03 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions containing pravastatin
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
CN100408029C (zh) * 2001-09-28 2008-08-06 麦克内尔-Ppc股份有限公司 有镶嵌部分的组合剂型
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
KR100592511B1 (ko) * 2002-12-30 2006-07-03 안경섭 벤즈이미다졸 유도체 또는 약리학적으로 허용되는 이의염을 활성물질로 하는 안정성이 강화된 방출제어형 제제및 그 제조방법
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US8449911B2 (en) * 2003-03-12 2013-05-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
EP1617842A1 (en) * 2003-04-22 2006-01-25 Dr. Reddy's Laboratories Ltd. Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
CA2543172A1 (en) * 2003-10-31 2005-05-19 Dexcel Ltd. Stable lansoprazole formulation
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005046634A2 (de) * 2003-11-14 2005-05-26 Siegfried Generics International Ag Magensaftresistente verabreichungsform
HU227317B1 (en) * 2003-11-25 2011-03-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Enteric coated tablet containing pantoprazole
KR100581967B1 (ko) * 2003-12-18 2006-05-22 한국유나이티드제약 주식회사 소화성 궤양 치료를 위한 프로톤펌프 저해제와클래리스로마이신을 함유하는 이중 펠렛 제제 및 그의제조방법
EP1699458A4 (en) * 2003-12-30 2012-04-25 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITION
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
CA2570796A1 (en) * 2004-06-15 2006-01-05 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of benzimidazole compounds
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
CN100364989C (zh) * 2004-09-30 2008-01-30 江苏豪森药业股份有限公司 拉唑类衍生物及其盐和用途
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
US20090208575A1 (en) * 2005-01-03 2009-08-20 Lupin Limited Pharmaceutical Composition Of Acid Labile Substances
KR100570446B1 (ko) * 2005-02-14 2006-04-12 지엘팜텍 주식회사 산 불안정성 약리활성물질 함유 장용성 경구용 제제 및 이의 제조방법
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
GB0514926D0 (en) * 2005-07-20 2005-08-24 Huntleigh Technology Plc Bed assembly
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
WO2007078271A2 (en) * 2005-12-20 2007-07-12 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
WO2007099433A2 (en) * 2006-02-28 2007-09-07 Wockhardt Ltd Delayed release dosage form of pantoprazole or salt thereof
KR101784001B1 (ko) 2006-04-04 2017-10-23 케이지 액퀴지션 엘엘씨 항혈소판제와 산 억제제를 포함하는 경구 투여용 약학 조성물
DE102006017896A1 (de) † 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
US9597293B2 (en) * 2007-05-07 2017-03-21 Evonik Röhm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
WO2009105568A1 (en) 2008-02-20 2009-08-27 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
US20110038933A1 (en) * 2008-05-06 2011-02-17 Dexcell Ltd. Stable benzimidazole formulation
DE102008045339A1 (de) * 2008-09-01 2010-03-04 Stada Arzneimittel Ag Pharmazeutisches Pellet
EP2344139A1 (en) * 2008-09-09 2011-07-20 AstraZeneca AB Method for delivering a pharmaceutical composition to patient in need thereof
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
JP5691142B2 (ja) * 2009-07-17 2015-04-01 ニプロ株式会社 ベンズイミダゾール系注射剤
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
CN102085188B (zh) * 2011-01-14 2013-01-02 寿光富康制药有限公司 一种兰索拉唑肠溶微丸的制备方法
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
WO2013141827A1 (en) 2012-03-21 2013-09-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Enteric coated solid pharmaceutical compositions for proton pump inhibitors
EP2933002A1 (en) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
ZA861026B (en) * 1985-02-13 1986-09-24 Ciba Geigy Ag Pesticidal compositions
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
SE9002206D0 (sv) * 1990-06-20 1990-06-20 Haessle Ab New compounds
WO1991019712A1 (en) * 1990-06-20 1991-12-26 Aktiebolaget Astra Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
MX9700152A (es) * 1994-07-08 1997-04-30 Astra Ab Nueva formulacion farmaceutica oral, que contiene sal de magnesio de omeprazol.
JP3350054B2 (ja) * 1994-07-08 2002-11-25 アストラゼネカ・アクチエボラーグ 複数単位の錠剤化された剤形▲ｉ▼
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process

Also Published As

Publication number Publication date
RU2170090C2 (ru) 2001-07-10
IS4359A (is) 1996-09-17
KR100405586B1 (ko) 2004-05-31
NO964271D0 (no) 1996-10-08
US6013281A (en) 2000-01-11
PL316685A1 (en) 1997-02-03
NO315925B1 (no) 2003-11-17
EE03379B1 (et) 2001-04-16
EE9600148A (et) 1997-04-15
ES2179175T3 (es) 2003-01-16
US20040234594A1 (en) 2004-11-25
ZA961078B (en) 1997-08-11
EP1174136A3 (en) 2003-04-23
FI964028A0 (sv) 1996-10-08
AU695774B2 (en) 1998-08-20
CN1146720A (zh) 1997-04-02
WO1996024338A1 (en) 1996-08-15
BR9605121A (pt) 1997-10-14
CA2186037A1 (en) 1996-08-15
DE69621523T2 (de) 2003-01-30
NO964271L (no) 1996-10-08
HUP9603112A3 (en) 2001-12-28
US20020012676A1 (en) 2002-01-31
HK1008302A1 (en) 1999-05-07
NZ301424A (en) 1998-07-28
HUP9603112A2 (en) 1997-08-28
JP3881377B2 (ja) 2007-02-14
US20020086029A1 (en) 2002-07-04
SK126196A3 (en) 1997-10-08
CN1182841C (zh) 2005-01-05
DE69621523D1 (de) 2002-07-11
EP0752851B1 (en) 2002-06-05
MX9604497A (es) 1997-11-29
UA44890C2 (uk) 2002-03-15
SK281202B6 (sk) 2001-01-18
TR199600785T1 (tr) 1997-08-21
IS1884B (is) 2003-08-15
CZ291720B6 (cs) 2003-05-14
EP1174136A2 (en) 2002-01-23
ATE218327T1 (de) 2002-06-15
FI964028A (sv) 1996-10-08
PT752851E (pt) 2002-11-29
FI119141B (sv) 2008-08-15
CZ291896A3 (en) 1997-07-16
EP0752851A1 (en) 1997-01-15
JPH09511768A (ja) 1997-11-25
DK0752851T3 (da) 2002-09-16
AU4683996A (en) 1996-08-27
PL184433B1 (pl) 2002-10-31
US20030113375A1 (en) 2003-06-19
CA2186037C (en) 2002-04-16

Similar Documents

Publication Publication Date Title
SE9500478D0 (sv) New pharmaceutical formulation and process
DE69628444D1 (de) Säurelabile omeprazol enthaltende pharmazeutische zusammensetzung und verfahren zu dessen herstellung
NZ505127A (en) Oral pharmaceutical extended release dosage form of proton pump inhibitor
MY102675A (en) Pharmaceutical formulations of acid labile substances for oral use.
SI1037634T1 (sl) Peroralna dajalna oblika, ki obsega inhibitor protonske crpalke (npr. pantoprazol)
ATE244002T1 (de) Pharmazeutische formulierung mit omeprazol
HU9301577D0 (en) Method for manufacturing peroral medical preparative
FI973733A0 (fi) Farmaceutiskt preparat och foerfarande foer dess framstaellning
UY24888A1 (es) Tabletas de oxacarbazepina recubiertas de pelicula
SE9700885D0 (sv) New pharmaceutical formulation
ATE442852T1 (de) Trimetazidine enthaltendes arzneimittel mit verzögerter wirkstoffabgabe und verfahren zur herstellung
NO975660D0 (no) Anvendelse av benzimidazoler for fremstilling av et medikament for behandling av levkemi
SE9003904D0 (sv) Method for the manufacture of a pharmaceutical dosage form
ES2024993A6 (es) Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
CY1110737T1 (el) Υποκατεστημενες ενωσεις 1,5-διαμινοπενταν-3-ολης
DE60120458D1 (de) Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen
FR2820600B1 (fr) Procede pour la fabrication d'un film electroluminescent et application d'un tel film
MY102850A (en) New pharmaceutical preparation for oral use.
TH19832A (th) สูตรผสมทางเภสัชกรรมชนิดใหม่ที่ประกอบรวมด้วยเกลือแมกนีเซียมของออเมพราโซลที่มีรูปแบบทางกายภาพชนิดใหม่และวิธีสำหรับการผลิตเกลือนี้
ECSP982406A (es) Tabletas de oxacarbazepina recubiertas de pelicula